Johannes K Ehinger1,2, Saori Morota1,3, Magnus J Hansson1,4, Gesine Paul5,6, Eskil Elmér1,7. 1. Mitochondrial Medicine Department of Clinical Sciences Lund University Lund Sweden. 2. Department of Otorhinolaryngology, Head and Neck Surgery Skåne University Hospital Lund Sweden. 3. Department of Human Genetics National Center for Child Health and Development Tokyo Japan. 4. Department of Clinical Physiology Skåne University Hospital Lund Sweden. 5. Translational Neurology Group, Department of Clinical Sciences Lund University Lund Sweden. 6. Department of Neurology Skåne University Hospital Lund Sweden. 7. Department of Clinical Neurophysiology Skåne University Hospital Lund Sweden.
Abstract
BACKGROUND: Patients with Huntington's disease display symptoms from both the central nervous system and peripheral tissues. Mitochondrial dysfunction has been implicated as part of the pathogenesis of the disease and has been reported in brain tissue and extracerebral tissues, such as muscle and blood cells, but the results are inconsistent. Therefore, the authors performed a refined evaluation of mitochondrial function in 2 types of peripheral blood cells from 14 patients with Huntington's disease and 21 control subjects. Several hypotheses were predefined, including impaired mitochondrial complex II function (primary), complex I function (secondary), and maximum oxidative phosphorylation capacity (secondary) in patient cells. METHODS: High-resolution respirometry was applied to viable platelets and mononuclear cells. Data were normalized to cell counts, citrate synthase activity, and mitochondrial DNA copy numbers. RESULTS: Normalized to citrate synthase activity, platelets from patients with Huntington's disease displayed respiratory dysfunction linked to complex I, complex II, and lower maximum oxidative phosphorylation capacity. No difference was seen in mononuclear cells or when platelet data were normalized to cell counts or mitochondrial DNA. The ratio of complex I respiration through maximum oxidative phosphorylation was significantly decreased in patients compared with controls. The corresponding ratio for complex II was unaffected. CONCLUSIONS: The data indicate decreased function of mitochondrial complex I in peripheral blood cells from patients with Huntington's disease, although this could not be uniformly confirmed. The results do not confirm a systemic complex II dysfunction and do not currently support the use of mitochondrial function in blood cells as a biomarker for the disease.
BACKGROUND: Patients with Huntington's disease display symptoms from both the central nervous system and peripheral tissues. Mitochondrial dysfunction has been implicated as part of the pathogenesis of the disease and has been reported in brain tissue and extracerebral tissues, such as muscle and blood cells, but the results are inconsistent. Therefore, the authors performed a refined evaluation of mitochondrial function in 2 types of peripheral blood cells from 14 patients with Huntington's disease and 21 control subjects. Several hypotheses were predefined, including impaired mitochondrial complex II function (primary), complex I function (secondary), and maximum oxidative phosphorylation capacity (secondary) in patient cells. METHODS: High-resolution respirometry was applied to viable platelets and mononuclear cells. Data were normalized to cell counts, citrate synthase activity, and mitochondrial DNA copy numbers. RESULTS: Normalized to citrate synthase activity, platelets from patients with Huntington's disease displayed respiratory dysfunction linked to complex I, complex II, and lower maximum oxidative phosphorylation capacity. No difference was seen in mononuclear cells or when platelet data were normalized to cell counts or mitochondrial DNA. The ratio of complex I respiration through maximum oxidative phosphorylation was significantly decreased in patients compared with controls. The corresponding ratio for complex II was unaffected. CONCLUSIONS: The data indicate decreased function of mitochondrial complex I in peripheral blood cells from patients with Huntington's disease, although this could not be uniformly confirmed. The results do not confirm a systemic complex II dysfunction and do not currently support the use of mitochondrial function in blood cells as a biomarker for the disease.
Authors: R H Swerdlow; J K Parks; D S Cassarino; A T Shilling; J P Bennett; M B Harrison; W D Parker Journal: Biochem Biophys Res Commun Date: 1999-08-11 Impact factor: 3.575
Authors: Fredrik Sjövall; Johannes K H Ehinger; Sigurður E Marelsson; Saori Morota; Eleonor Asander Frostner; Hiroyuki Uchino; Johan Lundgren; Einar Arnbjörnsson; Magnus J Hansson; Vineta Fellman; Eskil Elmér Journal: Mitochondrion Date: 2012-11-16 Impact factor: 4.160
Authors: A Sawa; G W Wiegand; J Cooper; R L Margolis; A H Sharp; J F Lawler; J T Greenamyre; S H Snyder; C A Ross Journal: Nat Med Date: 1999-10 Impact factor: 53.440
Authors: Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H Kraus; Horst Przuntek; Ludger Schöls Journal: Mov Disord Date: 2005-06 Impact factor: 10.338
Authors: Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre Journal: Nat Neurosci Date: 2002-08 Impact factor: 24.884
Authors: Wenjun Song; Jin Chen; Alejandra Petrilli; Geraldine Liot; Eva Klinglmayr; Yue Zhou; Patrick Poquiz; Jonathan Tjong; Mahmoud A Pouladi; Michael R Hayden; Eliezer Masliah; Mark Ellisman; Isabelle Rouiller; Robert Schwarzenbacher; Blaise Bossy; Guy Perkins; Ella Bossy-Wetzel Journal: Nat Med Date: 2011-02-20 Impact factor: 53.440
Authors: Raymond E Lai; Matthew E Holman; Qun Chen; Jeannie Rivers; Edward J Lesnefsky; Ashraf S Gorgey Journal: PLoS One Date: 2022-03-11 Impact factor: 3.240